Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osmetech has submitted eSensor 2C9/VKOR test to the FDA for 510(k) pre-marketing clearance. The test is to be used as an aid in the identification of patients at risk for increased sensitivity for the widely used blood-thinning drug, warfarin.
Subscribe to our email newsletter
Clinical studies were performed at three evaluation sites in the US using the company’s next generation eSensor XT-8 instrument. These followed the highly successful pre-clinical studies completed in November 2007 where 345 samples were tested using Osmetech’s eSensor 2C9/VKOR method and found to be in 100% agreement with results from bi-directional DNA Sequencing.
James White, CEO of Osmetech, said: “We are delighted with the performance of our warfarin test and are confident of achieving FDA clearance to launch our warfarin test in the first half of 2008.”